AR014743A1 - Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno - Google Patents

Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno

Info

Publication number
AR014743A1
AR014743A1 ARP990101194A ARP990101194A AR014743A1 AR 014743 A1 AR014743 A1 AR 014743A1 AR P990101194 A ARP990101194 A AR P990101194A AR P990101194 A ARP990101194 A AR P990101194A AR 014743 A1 AR014743 A1 AR 014743A1
Authority
AR
Argentina
Prior art keywords
useful
antigen
compositions
preparations
coli
Prior art date
Application number
ARP990101194A
Other languages
English (en)
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of AR014743A1 publication Critical patent/AR014743A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una composicion, que comprende un mutante distinto genéticamente de la enterotoxina térmicamente lábil de E. coli (LT).Específicamente, el mutante LT denominado LT(R192G/L211A) se modifica por dos sustituciones de aminoácidos, por ejemplo, la arginina en la posicion 192 delos aminoácidos se sustituye por glicina, y la leucina en la posicion 211 de los aminoácidos se sustituye por alanina. La holotoxina termolábil de E. colimutante presenta actividad inmunologica adyuvante y es: (a) substancialmente menos toxica que la holotoxina enterotoxina termolábil de E. coli naturalmedida en el ensayo de células adrenales Y-1; (b) substancialmente menos toxica que la holotoxina enterotoxina termolábil de E. coli naturalmedida en elensayo en ratones abiertos; y (c) menos toxica que una composicion que consiste de LT(R192G) aislada medida en el ensayo en ratones abiertos. Se puedeadministrar conjuntamente con un antígeno tal como bacterias, hongos, protozoarios, virus, helmintos y otros patogenos microbianos. Se describenademás las preparaciones y composiciones que la contienen conjuntamente con un antígeno y un kit util para la produccion de una respuesta inmune protectora enun huésped contra un patogeno.
ARP990101194A 1998-03-18 1999-03-18 Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno AR014743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/044,064 US6033673A (en) 1998-03-18 1998-03-18 Double mutant enterotoxin for use as an adjuvant

Publications (1)

Publication Number Publication Date
AR014743A1 true AR014743A1 (es) 2001-03-28

Family

ID=21930346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101194A AR014743A1 (es) 1998-03-18 1999-03-18 Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno

Country Status (4)

Country Link
US (1) US6033673A (es)
AR (1) AR014743A1 (es)
AU (1) AU3089399A (es)
WO (1) WO1999047167A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US20050175634A1 (en) * 1999-06-25 2005-08-11 The Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
CA2276219A1 (en) * 1999-06-25 2000-12-25 Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US7527802B2 (en) * 2001-02-13 2009-05-05 The United States Of America As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
CA2438921C (en) * 2001-02-21 2012-04-10 Shire Biochem Inc. Streptococcus pyogenes polypeptides and corresponding dna fragments
EP2316482A1 (en) 2001-03-19 2011-05-04 Intercell USA, Inc. Transcutaneous immunostimulation
EP1581256A4 (en) * 2002-11-14 2006-06-07 Pfizer Prod Inc USE OF RMLT AS MARKER ANTIGEN FOR VACCINE AND AS SYNERGISTIC ADJUVANS WITH AMPY
CN100387719C (zh) * 2005-05-09 2008-05-14 中国农业科学院生物技术研究所 编码大肠杆菌热敏毒素基因及其表达载体和用途
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2701168A1 (en) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
BR112014005601B1 (pt) 2011-09-12 2020-09-29 Scandinavian Biopharma Holding Ab Vacina oral para a imunização contra a diarréia induzida pela etec
CA2863083C (en) 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2014044690A1 (en) 2012-09-18 2014-03-27 Valneva Austria Gmbh Improved vaccines
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
WO2024083912A1 (en) 2022-10-19 2024-04-25 Glyprovac Aps Glycosylated yghj polypeptides from uropathogenic e. coli

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308835A (en) * 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant

Also Published As

Publication number Publication date
WO1999047167A1 (en) 1999-09-23
US6033673A (en) 2000-03-07
AU3089399A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
AR014743A1 (es) Composiciones de una enterotoxina de mutacion doble, utiles como adyuvantes, las preparaciones y composiciones que la contienen conjuntamentecon un antigeno y un kit util para la produccion de una respuesta inmune protectora en un huesped contra un patogeno
Pogoryelov et al. The oligomeric state of c rings from cyanobacterial F-ATP synthases varies from 13 to 15
BR0210216A (pt) Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante
Howe et al. Virus-erythrocyte interactions
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
ATE451386T1 (de) Mutantenformen von cholera holotoxin als adjuvans
Amitai et al. Distribution and function of new bacterial intein‐like protein domains
Scharf et al. Epidithiodiketopiperazine biosynthesis: A four‐enzyme cascade converts glutathione conjugates into transannular disulfide bridges
BRPI0606858A2 (pt) composições detergentes
Turbyfill et al. Assembly, biochemical characterization, immunogenicity, adjuvanticity, and efficacy of Shigella artificial invaplex
NO980881L (no) Fremgangsmater og blandinger for selektiv modifikasjon av nukleinsyrer
BR0108713A (pt) Expressão hìbrida de proteìnas de neisseria
CN103472235A (zh) 一种长效蛋白质溶液稳定剂
AR038375A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
EA200400329A1 (ru) Способы амплификации нуклеиновых кислот
TR200202233T2 (tr) Organik iyodürü organik ortamdan ayırma yöntemi.
Asuthkar et al. Expression and characterization of an iron-regulated hemin-binding protein, HbpA, from Leptospira interrogans serovar Lai
Taguchi et al. Monomeric chaperonin-60 and its 50-kDa fragment possess the ability to interact with non-native proteins, to suppress aggregation, and to promote protein folding.
Baweja et al. Properties of Bacillus anthracis spores prepared under various environmental conditions
Zhang et al. Isolation and characterization of ACTX-6: a cytotoxic L-amino acid oxidase from Agkistrodon acutus snake venom
BRPI0500921A (pt) composição adjuvante de alta performance empregada na formulação de herbicidas a base de derivados de n-fosfonometilglicina e seus sais
WO2002030964A3 (en) Comparative ligand mapping from mhc positive cells
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
Kitov et al. An entropically efficient supramolecular inhibition strategy for Shiga toxins